Remedium Lifecare Appoints New Directors and Restructures Board Committees

Remedium Lifecare Limited has announced significant changes to its board composition and committee structure, as per a recent filing with the BSE. The company's Board of Directors, in a meeting held on October 31, 2025, approved several key appointments and restructuring measures.

New Board Appointments

The company has made two notable appointments to its board:

Mr. Rambhajan Vishwakarma (DIN: 11360922) has been appointed as an Additional Director (Non-Executive, Non-Independent) and Chairman of the Board, effective October 31, 2025.
Mr. Vignesh Laxman Gawde (DIN: 11360925) has been appointed as an Additional Executive/Whole-time Director for a five-year term, also effective from October 31, 2025.

Both appointments are subject to shareholder approval within three months or at the next General Meeting, whichever is earlier.

Director Profiles

Director	Background	Appointment Details
Rambhajan Vishwakarma	B.A. from D.D.U. Gorakhpur; Over 15 years of experience in banking products sales, including roles at ICICI Bank	Additional Non-Executive, Non-Independent Director and Chairman
Vignesh Laxman Gawde	M.Sc. in Physical Chemistry from Mumbai University; Research Associate at AJANTA PHARMA LTD	Additional Executive/Whole-time Director; Monthly remuneration of Rs. 50,000

Board Committee Restructuring

The company has reconstituted four key committees:

Audit Committee: Now chaired by Mr. Vijay Pal Singh Gulya (Independent Director)
Nomination and Remuneration Committee: Chaired by Mrs. Shamim Adil Michal (Independent Director)
Stakeholders Relationship Committee: Chaired by Mr. Rambhajan Vishwakarma
Risk Management Committee: Chaired by Mrs. Shamim Adil Michal

It's worth noting that the Nomination and Remuneration Committee was dissolved prior to these appointments due to director resignations, which prevented their recommendation for the new appointments.

Postal Ballot and Other Approvals

The board has approved postal ballot notices for:

Change of the company name
Regularization of Mr. Rambhajan Vishwakarma's appointment
Regularization and remuneration approval for Mr. Vignesh Laxman Gawde

The e-voting for these resolutions is scheduled to conclude on December 7, 2025.

These changes mark a significant restructuring of Remedium Lifecare's leadership and governance structure, potentially signaling a new direction for the company's operations and strategy.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-3.85%	-3.23%	-3.85%	-17.58%	-65.03%	+650.00%

Remedium Lifecare has announced an ambitious strategic roadmap aimed at achieving 4X growth, backed by a robust financial performance in the first quarter of the fiscal year. The company, a key player in the pharmaceutical supply chain and specialty chemicals sector, has outlined a four-pillar strategy to drive its expansion and innovation efforts.

Strategic Roadmap for Growth

The company's growth strategy focuses on four key areas:

Advanced Manufacturing: Remedium plans to upgrade its existing Contract Development & Manufacturing Organization (CDMO) facilities and expand capacity to meet rising global demand. The company will also implement backward integration initiatives to optimize costs and improve margins.
Global Export Expansion: The pharmaceutical firm aims to strengthen its international footprint by entering new markets and deepening its presence in existing ones. Enhanced supply chain capabilities and strategic working capital deployment will support this global push.
Innovation and R&D Excellence: Remedium will establish a dedicated quality control laboratory and scale up research across therapeutic areas including anti-infectives, cardiovascular, and central nervous system (CNS) treatments. This move is expected to accelerate product development, ensure regulatory compliance, and bolster the company's innovation pipeline.
Product Diversification: The company plans to broaden its specialty chemical and pharmaceutical portfolio, aiming to serve evolving market needs, ensure resilience against sectoral fluctuations, and expand revenue streams.

Strong Q1 Performance

Remedium Lifecare has reported impressive financial results for Q1:

Metric	Q1	Q4	YoY Change
Profit After Tax (PAT)	₹464.88	(₹204.60)	327%
EBITDA Growth	-	-	508%

Notably, the Q1 PAT has already surpassed the entire previous fiscal year's PAT of ₹212.94 lakh, demonstrating strong operational execution and financial discipline.

Successful Rights Issue

The company successfully concluded an oversubscribed Rights Issue, raising ₹47.88 crore against applications totaling ₹51.86 crore. This capital infusion is expected to support the implementation of the company's growth strategy.

Management Commentary

Adarsh Munjal, Managing Director of Remedium Lifecare, commented on the company's performance and strategy: "This quarter marks a turning point for Remedium Lifecare. Delivering a PAT that surpasses our entire previous fiscal year's profit demonstrates the strength of our business model and operational agility. The successful Rights Issue and our focused 4-point strategy provide us with a powerful foundation to achieve 4X growth and create sustainable value for our stakeholders."

Looking Ahead

With its strong Q1 performance and clear strategic direction, Remedium Lifecare is positioning itself for consistent profitability, improved margins, and accelerated global reach. The company's focus on operational efficiency combined with a clear innovation agenda sets the stage for capturing emerging opportunities in both domestic and international markets.

As Remedium Lifecare embarks on this ambitious growth journey, investors and industry observers will be keenly watching the execution of its 4-point strategy and its impact on the company's market position in the pharmaceutical and specialty chemicals sectors.